What Happens to PML Risk After Stopping Tysabri?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy of Drug Safety Monitoring

If you or a loved one has taken Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML) even after stopping the medication. This concern is valid, as the legacy of post-marketing surveillance has shown that PML can occur months after discontinuation. This page reviews the evidence on PML timing, risk factors, and the importance of continued monitoring after Tysabri cessation.

Tysabri and PML: Mechanism and Risk Factors

Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, highlighting this risk and mandating that the drug be available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML compared to those who are seronegative (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML is variable and may include progressive neurological deficits such as cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Healthcare professionals are instructed to monitor patients on Tysabri for any new sign or symptom suggestive of PML and to withhold dosing immediately at the first indication of such symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Diagnosis typically involves brain imaging, cerebrospinal fluid analysis for JCV DNA, and sometimes brain biopsy. The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrin on the surface of lymphocytes, inhibiting their adhesion to vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells. This prevents lymphocyte migration across the blood-brain barrier into the central nervous system (CNS). While this reduces inflammation in multiple sclerosis, it also impairs immune surveillance in the CNS, allowing latent JCV to reactivate and cause PML. The drug's immunosuppressive effect is particularly pronounced in the brain, where normal T-cell trafficking is disrupted.

Evidence from Clinical Trials and Post-Marketing Surveillance

In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has identified numerous adverse events associated with Tysabri, though PML is not listed among the most frequently reported events in that database. The most common FAERS reports include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), and gait disturbance (9,422 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These data reflect the underlying disease and general adverse effects rather than PML specifically. The adequacy of warnings regarding Tysabri and PML is addressed by the boxed warning and the TOUCH Prescribing Program, which require prescribers and patients to be educated about the risk. The warning explicitly states that PML usually leads to death or severe disability and lists the three known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Causation Considerations for Affected Patients

For affected patients, causation considerations involve establishing that PML developed during or after Tysabri treatment, with no other clear cause of immunosuppression. The timeline between exposure and documented harm can vary. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data suggest that risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The presence of anti-JCV antibodies further stratifies risk, with seropositive patients having a higher likelihood of developing PML. In summary, Tysabri is associated with a well-documented risk of PML, which is communicated through FDA warnings and a restricted distribution program. The mechanistic basis involves impaired CNS immune surveillance due to inhibition of lymphocyte trafficking. Risk factors include anti-JCV antibody status, treatment duration, and prior immunosuppressant use. Patients and healthcare providers must remain vigilant for early signs of PML to enable prompt intervention.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning for Tysabri regarding PML?

The FDA has issued a boxed warning for Tysabri (natalizumab) highlighting the increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The warning mandates that Tysabri be available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How does Tysabri cause PML?

Tysabri is an alpha-4 integrin antagonist that prevents lymphocyte migration across the blood-brain barrier, impairing immune surveillance in the central nervous system. This allows latent JC virus to reactivate and cause PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.